News >

Multiagent Regimens Continue to Spearhead Progress in Late Relapsed Myeloma

Gina Columbus @ginacolumbusonc
Published: Tuesday, Aug 13, 2019

Peter Voorhees, MD

Peter Voorhees, MD
It is already a necessity to incorporate triplet regimens into clinical practice for patients with late relapsed/refractory multiple myeloma, and more intriguing multiagent approaches utilizing proteasome inhibitors, CD38-targeted monoclonal antibodies, immunomodulatory agents, and now XPO1 inhibitors are poised to take this part of the paradigm to the next level, explained Peter Voorhees, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication